3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Prostatic Neoplasms
22
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer
2
Non-metastatic, Hormone naïve Prostate Cancer
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Adenocarcinoma of the Prostate
1
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Androgen Antagonists
×
Clear all
NCT04191096
2026-04-29
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3
Completed
1,251 enrolled
15 charts
NCT04934722
2025-10-01
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3
Completed
186 enrolled
14 charts